세계의 트루리시티 시장 보고서 : 역학, 파이프라인 분석, 시장 인사이트 및 예측(2025년)
Trulicity Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
상품코드 : 1763103
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

트루리시티 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9%로 성장할 전망이며, 111억 8,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 디지털 헬스 기술 채용 증가, 사람들의 건강 의식 향상, 교육 및 계발 프로그램 증가, 혁신적인 치료에 대한 수요 증가, 헬스케어 활동에 대한 액세스 증가 등에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 기술 통합, 전략적 제휴, 제품 혁신, 개별화 의약품에 대한 주력, 병용요법, 지속가능한 대처 등을 들 수 있습니다.

당뇨병 인구 증가는 트루리시티 시장의 성장을 크게 촉진할 것으로 예측됩니다. 당뇨병은 체내에서 인슐린을 효과적으로 생성하거나 사용할 수 없기 때문에 혈당이 높아지는 것을 특징으로 하는 만성질환으로 도시화, 건강하지 못한 식생활, 운동부족, 유전적 소인 등의 요인에 의해 증가하고 있습니다. 당뇨병 유병률 증가는 혈당을 관리하고 환자의 예후를 개선하는 트루리시티를 포함한 효과적인 치료에 대한 수요를 높이고 있습니다. 예를 들어 2024년 3월 Office for Health Improvement and Disparities는 잉글랜드에서 포괄적인 치료를 받고 있는 1형 당뇨병 환자의 비율이 2022년 35.2%에서 2023년 43.8%로 증가했다고 보고했습니다. 이는 당뇨병 관리에 대한 관심의 고조를 반영한 것이며, 트루리시티의 시장 잠재력을 강조하는 것입니다.

트루리시티 시장의 주요 동향은 주요 심혈관계 유해 사건의 위험을 줄이기 위한 혁신적인 제제의 개발입니다. 트루리시티는 주 1회 투여 주사약으로 GLP-1의 작용을 모방해 인슐린 분비를 촉진하고 위 배출을 지연시키며 식욕을 감퇴시키고 혈당 관리를 개선합니다. 2022년 11월 미국 제약회사 일라이릴리앤컴퍼니는 트루리시티에 대해 10세 이상 성인과 소아의 제2형 당뇨병(T2DM) 환자의 혈당 조절 개선을 위한 식이요법 및 운동 요법 보조제로 FDA 승인을 획득했습니다. 이 승인은 당뇨병 환자의 심혈관 위험 저감에 효과적임을 증명하는 임상검사 성공에 이은 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오 의약품 시장에서의 제품 특성

제4장 시장 동향 및 전략

제5장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석 및 전략 분석 프레임워크

제7장 세계의 시장 가격 분석 및 예측

제8장 시장 세분화

제9장 세계의 임상 적응증 시장 역학

제10장 지역별 및 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도 및 기업 프로파일

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹 및 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 부문 및 전략

제34장 부록

AJY
영문 목차

영문목차

Trulicity is a prescription medication containing the active ingredient dulaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. It is used to improve blood sugar control in adults with type 2 diabetes, often in combination with other medications. Administered as a once-weekly injection, it may also support weight loss and reduce the risk of cardiovascular events.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of trulicity are the prefilled syringe package and the vial package. A prefilled syringe package is a medical container that holds a single dose of the medication, pre-filled by the manufacturer. This ensures precise dosing, minimizes contamination risk, and provides convenience for both healthcare providers and patients. It is used in managing type 2 diabetes, glycemic control, weight management, and reducing cardiovascular risks, and is distributed through hospital pharmacies, retail pharmacies, and online platforms.

The trulicity market research report is one of a series of new reports from The Business Research Company that provides trulicity market statistics, including the trulicity industry's global market size, regional shares, competitors with a trulicity market share, detailed trulicity market segments, market trends and opportunities, and any further data you may need to thrive in the trulicity industry. This trulicity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The trulicity market size is expected to see strong growth in the next few years. It will grow to $11,180 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to raising adoption of digital health technologies, raising health awareness among people, increasing educational and awareness programs, growing demand for innovative therapies, increasing access to healthcare activities. Major trends in the forecast period include technological integration, strategic collaboration, product innovation, focus on personalized medicines, combination therapies, sustainable initiatives.

The increasing diabetes population is expected to significantly propel the growth of the trulicity market. Diabetes, a chronic condition characterized by high blood sugar levels due to the body's inability to produce or use insulin effectively, is rising due to factors such as urbanization, unhealthy diets, physical inactivity, and genetic predisposition. The growing prevalence of diabetes is increasing the demand for effective treatments, including Trulicity, which helps manage blood sugar levels and improves patient outcomes. For instance, in March 2024, the Office for Health Improvement and Disparities reported that the percentage of people with type 1 diabetes receiving comprehensive care in England increased from 35.2% in 2022 to 43.8% in 2023. This reflects a rising focus on managing diabetes and underscores the market potential for trulicity.

A key trend in the trulicity market is the development of innovative formulations to reduce the risk of major adverse cardiovascular events. Trulicity is a once-weekly injectable medication that mimics the action of GLP-1, enhancing insulin secretion, slowing gastric emptying, and reducing appetite, which helps improve blood sugar management. In November 2022, Eli Lilly and Company, a US-based pharmaceutical company, received FDA approval for Trulicity as an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes mellitus (T2DM). This approval followed a successful clinical trial demonstrating its effectiveness in reducing cardiovascular risks in diabetes patients.

A significant trend in the trulicity market is the focus on expanding biologics production facilities to meet rising demand and gain a competitive advantage. Biologics production facilities are specialized plants designed to manufacture complex biologic drugs, such as monoclonal antibodies, vaccines, and cell and gene therapies, which require advanced manufacturing processes. For instance, Eli Lilly and Company, a major player in the market, has committed to substantial investments to enhance its manufacturing capacity. In January 2023, Lilly invested $450 million to expand its North Carolina plant, boosting production of Trulicity, its diabetes treatment. This expansion is part of a broader $1.7 billion investment in the facility, with full production expected to begin in 2027. Additionally, Lilly is constructing two new facilities in Indiana and investing €400 million in biologics production in Ireland. These moves reflect the company's strategy to support growing demand for its products and ensure continued innovation in biologics manufacturing.

Major players operating in the trulicity market are Eli Lilly And Company and Novo Nordisk.

North America was the largest region in the trulicity market in 2024. The regions covered in trulicity report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the trulicity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The trulicity market consists of sales of trulicity (Dulaglutide) injection, trulicity 3 mg and 4.5 mg, and trulicity (Dulaglutide) 0.75 mg and 1.5 mg. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Trulicity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on trulicity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for trulicity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trulicity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Trulicity Market Characteristics

3. Trulicity Market Biologic Drug Characteristics

4. Trulicity Market Trends And Strategies

5. Trulicity Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Trulicity Growth Analysis And Strategic Analysis Framework

7. Global Trulicity Market Pricing Analysis & Forecasts

8. Trulicity Market Segmentation

9. Global Trulicity Market Epidemiology Of Clinical Indications

10. Trulicity Market Regional And Country Analysis

11. Asia-Pacific Trulicity Market

12. China Trulicity Market

13. India Trulicity Market

14. Japan Trulicity Market

15. Australia Trulicity Market

16. South Korea Trulicity Market

17. Western Europe Trulicity Market

18. UK Trulicity Market

19. Germany Trulicity Market

20. France Trulicity Market

21. Eastern Europe Trulicity Market

22. North America Trulicity Market

23. USA Trulicity Market

24. Canada Trulicity Market

25. South America Trulicity Market

26. Middle East Trulicity Market

27. Africa Trulicity Market

28. Trulicity Market Competitive Landscape And Company Profiles

29. Global Trulicity Market Pipeline Analysis

30. Global Trulicity Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Trulicity Market

32. Recent Developments In The Trulicity Market

33. Trulicity Market High Potential Countries, Segments and Strategies

34. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기